Sensitivity (95% CI) | Specificity (95% CI) | Unadjusted PPV (95% CI) | Adjusted PPV* (95% CI) | Unadjusted NPV (95% CI) | OR (95% CI) | |
---|---|---|---|---|---|---|
S5 cutoff 3.7 | ||||||
CIN2+ | 62.0 (50.4–72.7) | 73.0 (66.9–78.5) | 43.4 (34.0–53.0) | 20.3 (16.7–23.9) | 85.2 (79.6–89.8) | 4.20 (2.59–7.54) |
CIN3+ | 70.3 (56.7–81.8) | 76.6 (70.7–81.9) | 45.0 (35.0–55.3) | 18.0 (14.3–21.7) | 90.5 (85.0–94.2) | 7.75 (4.21–14.3) |
S5 cutoff 0.8 | ||||||
CIN2+ | 86.1 (76.5–92.8) | 40.1 (33.8–46.6) | 32.4 (26.1–39.2) | 13.8 (11.5–16.0) | 89.6 (82.2–94.7) | 4.14 (2.10–8.14) |
CIN3+ | 92.5 (91.8–97.9) | 38.8 (32.9–45) | 23.3 (17.8–29.6) | 9.9 (8.0–11.9) | 96.2 (90.6–99.0) | 7.76 (3.83–21.2) |
HPV16/18 and cytology for CIN2+ | ||||||
HPV16/18+ | 63.3 (51.7–73.9) | 29.1 (23.4–35.3) | 22.9 (17.5–29.1) | 9.0 (7.2–10.9) | 70.4 (60.3–79.2) | 0.71 (0.42–1.21) |
ASCUS+ | 57.0 (45.3–68.1) | 62.4 (55.9–68.6) | 33.6 (25.7–42.2) | 14.4 (11.5–17.3) | 81.3 (74.9–86.7) | 2.20 (1.3–3.7) |
LSIL+ | 51.9 (40.4–63.3) | 68.8 (62.5–74.6) | 35.7 (26.9–45.1) | 15.6 (12.3–18.8) | 81.1 (75.0–86.3) | 2.38 (1.42–3.99) |
HSIL+ | 27.8 (18.3–39.1) | 95.8 (92.8–98.0) | 68.8 (50.0–83.9) | 42.3 (34.0–50.6) | 79.9 (74.8–84.4) | 8.70 (3.9–19.2) |